Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2021

Open Access 01-12-2021 | Acute Lymphoblastic Leukemia | Research

Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients

Authors: Titi Sahidah Fitriana, Fredrick Dermawan Purba, Rina Rahmatika, Riski Muhaimin, Nur Melani Sari, Gouke Bonsel, Elly Stolk, Jan J. V. Busschbach

Published in: Health and Quality of Life Outcomes | Issue 1/2021

Login to get access

Abstract

Background

The adult versions EQ-5D-3L and EQ-5D-5L have been extensive compared. This is not the case for the EQ-5D youth versions. The study aim was to compare the measurement properties and responsiveness of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients.

Methods

A sample of patients 8–16 years old with different diseases and a wide range of disease severity was asked to complete EQ-5D-Y-3L, EQ-5D-Y-5L, PedsQL Generic Core Scale, and selected, appropriate disease-specific instruments, three times. EQ-5D-Y-3L and EQ-5D-Y-5L were compared in terms of: feasibility, (re-)distribution properties, discriminatory power, convergent validity, test–retest reliability, and responsiveness.

Results

286 participating patients suffered from one of the following diseases: major beta-thalassemia, haemophilia, acute lymphoblastic leukaemia, acute illness. Missing responses were comparable between versions of the EQ-5D-Y, suggesting comparable feasibility. The number of patients in the best health state (level profile 11111) was equal in both EQ-5D-Y versions. The projection of EQ-5D-Y-3L scores onto EQ-5D-Y-5L for all dimensions showed that the two additional levels in EQ-5D-Y-5L slightly improved the accuracy of patients in reporting their problems, especially if severe. Convergent validity with PedsQL and disease-specific measures showed that the two EQ-5D-Y versions performed about equally. Test–retest reliability (EQ-5D-Y-3L 0.78 vs EQ-5D-Y-5L 0.84), and sensitivity for detecting health changes, were both better in EQ-5D-Y-5L.

Conclusions

Extending the number of levels did not give clear superiority to EQ-5D-Y-5L over EQ-5D-Y-3L based on the criteria assessed in this study. However, increasing the number of levels benefitted EQ-5D-Y performance in the measurement of moderate to severe problems and especially in longitudinal study designs.
Appendix
Available only for authorised users
Literature
1.
2.
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedPubMedCentralCrossRef
3.
Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–86.PubMedPubMedCentralCrossRef
4.
Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burström K, Cavrini G, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res. 2010;19(6):887–97.PubMedPubMedCentralCrossRef
5.
Scott D, Ferguson GD, Jelsma J. The use of the EQ-5D-Y health related quality of life outcome measure in children in the Western Cape, South Africa: psychometric properties, feasibility and usefulness - a longitudinal, analytical study. Health Qual Life Outcomes. 2017;15(1):12.PubMedPubMedCentralCrossRef
6.
Bergfors S, Åström M, Burström K, Egmar AC. Measuring health-related quality of life with the EQ-5D-Y instrument in children and adolescents with asthma. Acta Paediatr. 2015;104(2):167–73.PubMedCrossRef
7.
Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr. 2009;9:55.PubMedPubMedCentralCrossRef
8.
Otto C, Barthel D, Klasen F, Nolte S, Rose M, Meyrose AK, et al. Predictors of self-reported health-related quality of life according to the EQ-5D-Y in chronically ill children and adolescents with asthma, diabetes, and juvenile arthritis: longitudinal results. Qual Life Res. 2018;27(4):879–90.PubMedCrossRef
9.
Kreimeier S, Åström M, Burström K, Egmar A-C, Gusi N, Herdman M, et al. EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories. Quality of Life Res. 2019;5:1–11.
10.
Buchholz I, Thielker K, Feng YS, Kupatz P, Kohlmann T. Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Qual Life Res. 2015;24(4):829–35.PubMedCrossRef
11.
Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675–97.PubMedPubMedCentralCrossRef
12.
Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Fusco F, Gaeta L, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res. 2013;22(7):1707–16.PubMedCrossRef
13.
Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.PubMedCrossRef
14.
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health. 2008;11(2):275–84.PubMedCrossRef
15.
Wong CKH, Cheung PWH, Luo N, Cheung JPY. A head-to-head comparison of five-level (EQ-5D-5L-Y) and three-level EQ-5D-Y questionnaires in paediatric patients. Eur J Health Econ. 2019;5:1–10.
16.
Wong CKH, Cheung PWH, Luo N, Lin J, Cheung JPY. Responsiveness of EQ-5D youth version 5-level (EQ-5D-5L-Y) and 3-level (EQ-5D-3L-Y) in patients with idiopathic scoliosis. Spine. 2019;44(21):1507–14.PubMedCrossRef
17.
Pei W, Yue S, Zhi-Hao Y, Ruo-Yu Z, Bin W, Nan L. Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China. Eur J Health Econ. 2021;5:1–11.
18.
Zhou W, Shen A, Yang Z, Wang P, Wu B, Herdman M, et al. Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies. Eur J Health Econ. 2021;5:1–11.
19.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–8.PubMedCrossRef
20.
Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia. Indian J Pediatr. 2007;74(8):727–30.PubMedCrossRef
21.
Sadowski H, Kolvin I, Clemente C, Tsiantis J, Baharaki S, Ba G, et al. Psychopathology in children from families with blood disorders: a cross-national study. Eur Child Adolesc Psychiatry. 2002;11(4):151–61.PubMedCrossRef
22.
23.
Harijadi H, Gatot D, Akib AAP. The prevalence of factor VIII inhibitor in patients with severe hemophilia-A and its clinical characteristics. Paediatr Indones. 2005;45(4):177–81.CrossRef
24.
Nagel K, Walker I, Decker K, Chan AK, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia. 2011;17(6):872–4.PubMedCrossRef
25.
Gringeri AV, Von Mackensen S, Auerswald G, Bullinger M, Garrido RP, Kellermann E, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia. 2004;10:26–33.PubMedCrossRef
26.
Pui CH. Acute Lymphoblastic Leukemia. Encyclopedia of Cancer. Schwab M ed. Berlin, Heidelberg: Springers; 2011.
27.
Sitaresmi MN, Mostert S, Gundy CM, Sutaryo, Veerman AJ (2008) Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia. Health Qual Life Outcomes 6:96.
28.
Sung L, Yanofsky R, Klaassen RJ, Dix D, Pritchard S, Winick N, et al. Quality of life during active treatment for pediatric acute lymphoblastic leukemia. Int J Cancer. 2011;128(5):1213–20.PubMedCrossRef
29.
van Litsenburg RRL, Huisman J, Hoogerbrugge PM, Egeler RM, Kaspers GJL, Gemke RJBJ. Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study. Health Qual Life Outcomes. 2011;9(1):25.PubMedPubMedCentralCrossRef
30.
Varni JW, Seid M, Kurtin PS. PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care. 2001:800–12.
31.
Varni JW, Seid M, Knight TS, Uzark K, Szer IS. The PedsQLTM 4.0 Generic Core Scales: Sensitivity, responsiveness, and impact on clinical decision-making. J Behav Med. 2002;25(2):175–93.PubMedCrossRef
32.
Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQLTM in pediatric cancer: reliability and validity of the pediatric quality of life inventoryTM generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–106.PubMedCrossRef
33.
Klaassen RJ, Barrowman N, Merelles-Pulcini M, Vichinsky EP, Sweeters N, Kirby-Allen M, et al. Validation and reliability of a disease-specific quality of life measure (the T ran Q ol) in adults and children with thalassaemia major. Br J Haematol. 2014;164(3):431–7.PubMedCrossRef
34.
Poengoet B, Sungkar E, Pandji TD. Quality of life in thalassemia major patients: reliability and validity of Indonesian version of TranQol Questionnaire. Int J Integr Health Sci. 2017;5(2):75–9.CrossRef
35.
Mercan A, Sarper N, Inanir M, Mercan HI, Zengin E, Kilic SC, et al. Hemophilia-Specific Quality of Life Index (Haemo-QoL and Haem-A-QoL questionnaires) of children and adults: result of a single center from Turkey. Pediatr Hematol Oncol. 2010;27(6):449–61.PubMedCrossRef
36.
Von Mackensen S, Bullinger M, Haemo-Qo LG. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia. 2004;10:17–25.CrossRef
37.
Uwer L, Rotonda C, Guillemin F, Miny J, Kaminsky MC, Mercier M, et al. Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer. Health Qual Life Outcomes. 2011;9:70.PubMedPubMedCentralCrossRef
38.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.PubMedCrossRef
39.
Stolk EA, Busschbach JJV. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res. 2003;12(4):363–71.PubMedCrossRef
40.
Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL. A comparison of Cohen’s Kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med Res Methodol. 2013;13(1):61.PubMedPubMedCentralCrossRef
41.
Gwet KL. Computing inter-rater reliability and its variance in the presence of high agreement. Br J Math Stat Psychol. 2008;61(Pt 1):29–48.PubMedCrossRef
42.
Rowen D, Keetharuth A, Poku E, Wong R, Pennington B, Wailoo A. A review of the psychometric performance of child and adolescent preference-based measures used to generate utility values for children. 2020.
43.
Arifin B, Purba FD, Herman H, Adam JMF, Atthobari J, Schuiling-Veninga CCM, et al. Comparing the EQ-5D-3 L and EQ-5D-5 L: studying measurement and scores in Indonesian type 2 diabetes mellitus patients. Health Qual Life Outcomes. 2020;18(1):22.PubMedPubMedCentralCrossRef
44.
Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL™* 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambulatory pediatrics. 2003;3(6):329–41.
45.
Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010;54(1):92–7.PubMedPubMedCentralCrossRef
Metadata
Title
Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients
Authors
Titi Sahidah Fitriana
Fredrick Dermawan Purba
Rina Rahmatika
Riski Muhaimin
Nur Melani Sari
Gouke Bonsel
Elly Stolk
Jan J. V. Busschbach
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2021
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-021-01889-4

Other articles of this Issue 1/2021

Health and Quality of Life Outcomes 1/2021 Go to the issue

Research

Response shift in health-related quality of life measures in the presence of formative indicators

Research

Self-management behavior and fasting plasma glucose control in patients with type 2 diabetes mellitus over 60 years old: multiple effects of social support on quality of life

Research

Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer

Research

Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey

Research

Translation and psychometric evaluation of the Chinese version of the resilience scale for children with cancer

Research

Translation, adaption and validation of the total nasal symptom score (TNSS) for Lithuanian population